MHH-ES1 Cells

The MHH-ES1 cell line is derived from a patient with Ewing sarcoma, a highly aggressive bone and soft tissue cancer predominantly affecting children and young adults. This cell line is a valuable model for studying the molecular mechanisms underlying Ewing sarcoma, particularly the role of the EWSR1-FLI1 fusion gene, which is characteristic of this cancer type. The fusion gene results from a translocation between chromosomes 11 and 22, leading to the production of an oncogenic transcription factor that drives tumorigenesis. MHH-ES1, like other Ewing sarcoma cell lines, is utilized to investigate the pathways influenced by EWSR1-FLI1, including alterations in cell proliferation, differentiation, and apoptosis. Researchers use the MHH-ES1 cell line to evaluate the efficacy of various therapeutic agents targeting pathways critical for Ewing sarcoma survival and proliferation. For example, it is instrumental in testing small molecule inhibitors, RNA interference, and CRISPR-Cas9 gene editing techniques aimed at disrupting the EWSR1-FLI1 fusion gene or its downstream effectors. Additionally, MHH-ES1 serves as a model to study resistance mechanisms to conventional chemotherapy and to identify novel biomarkers for early diagnosis and treatment response monitoring in Ewing sarcoma patients. Bone cancer cell lines, Bone, Ewing's Sarcoma, Growth Conditions: Adherent, clusters, Biosafety level: BSL 1